WO2003011340A1 - Formulation medicamenteuse destinee a une utilisation topique aux fins de therapie et de prophylaxie d'hyperhydrose - Google Patents
Formulation medicamenteuse destinee a une utilisation topique aux fins de therapie et de prophylaxie d'hyperhydrose Download PDFInfo
- Publication number
- WO2003011340A1 WO2003011340A1 PCT/EP2002/008101 EP0208101W WO03011340A1 WO 2003011340 A1 WO2003011340 A1 WO 2003011340A1 EP 0208101 W EP0208101 W EP 0208101W WO 03011340 A1 WO03011340 A1 WO 03011340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyperhidrosis
- glycopyrrolate
- salts
- derivatives
- enantiomers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- the invention relates to a pharmaceutical formulation for topical use for the therapy and prophylaxis of hyperhidrosis axillary, palmaris et plantaris and other forms of hyperhidrosis.
- This pharmaceutical formulation is based on the use of glycopyrrolate, its salts and / or its derivatives.
- glycopyrronium bromide with the chemical formula 3- (cyclopentylhydroxyphenyl-acetoxy) -1, 1-dimethylpyrronium bromide is a spasmolytic, anticholinergic (parasympatholytic)
- GPB has an effect.
- the mechanism of action is due to a blockade of the muscarinic receptors.
- the strong hydrophilicity of GPB prevents passage through the blood-brain barrier and thus central effects.
- the molar mass of the glycopyrronium bromide is 398.36 g / mol and the melting point of the compound is 193-198 ° C.
- GPB is a white powder.
- the stability of this compound is pH-dependent, the stability decreasing at a pH> 6.
- GPB is a slightly water-soluble compound.
- GPB has so far been used primarily as a secretion-inhibiting and spasmolytic substance in adjuvant therapy with special anesthetic or surgical procedures.
- BTX botulinum toxin
- a pharmaceutical formulation for topical use for the therapy and prophylaxis of hyperhidrosis axillary, palamaris et plantaris and / or other forms of hyperhidrosis is provided.
- This pharmaceutical formulation contains a glycopyrrolate, its salts and / or its derivatives and / or its enantiomers in an amount between 0.05 and 20% by weight.
- a gel and / or colloid-containing carrier system is used as the vehicle system.
- the application is not locally restricted here; rather, these vehicle systems enable the pharmaceutical formulation according to the invention to can be easily applied in the armpit area, for example, and even with increased sweat secretion, the penetration of the active ingredient can be ensured over a longer period of time compared to aqueous solutions.
- glycopyrrolate, its salts and / or its derivatives are preferably used in a concentration of between 0.5 and 5% by weight.
- Glycopyrronium bromide is preferably used as the salt of the glycopyrrolate.
- hydroxyethyl cellulose gel is preferably used.
- glycopyrrolate, its salts and / or its derivatives and / or its enantiomers for the manufacture of a medicament for topical use for the therapy and prophylaxis of hyperhidrosis axillaris, palmaris et plantaris and / or other forms of hyperhidrosis is also used according to the invention taught.
- the compound is used in a concentration between 0.05 to 20% by weight, preferably between 0.5 and 5% by weight.
- Three concentrations were placebo-controlled with GPB (0.5; 2.0; 4.0%) in hydroxyethyl cellulose gel (hydroxyethyl cellulose 10000 2.5 parts; glycerol 85% 10.0 parts; water (cons.) 87, 5 parts) examined for their effectiveness.
- the hyperhidrosis was objectified using quantitative hidroiuetry.
- Group 1 1 week 3 times a day + 3 weeks 1 time a day
- Group 2 2 weeks 2 times a day + 2 weeks 1 time a day
- Group 3 1 week 3 times a day + 1 week 2 times a day + 2 weeks 1 time a day
- Group 4 4 weeks 3 times a day
- the hyperhidrosis was objectified using quantitative hydrometry.
- the analysis of variance was used to analyze three and more samples (treatment groups) from normally distributed populations with the same variance. Since only one factor, the influence of the investigational medicinal product, was to be examined in the various mean value groups, the one-way analysis of variance (one-way ANOVA) was used. Here random samples with unknown common variance are examined. In addition, the differences between the individual groups will be examined using the Scheffe assessment of linear contrasts. For comparison of three or more independent groups, the Kruskal-Wallis-Test (H-Test) was offered, which tests the analog hypotheses of the one-way analysis of variance as a non-parametric test. The unpaired t-test was used to compare two samples with the same variance. Differences with an error probability of p ⁇ 0.05 were rated as statistically significant.
- H-Test Kruskal-Wallis-Test
- test preparations were stored in 75 ml glass jars with a ball attachment.
- hydroxyethyl cellulose gel as a vehicle system is only suitable for the therapy of hyperhidrosis axillaris, but not for hyperhidrosis palmaris (FIG. 2).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10136404.0 | 2001-07-26 | ||
DE2001136404 DE10136404A1 (de) | 2001-07-26 | 2001-07-26 | Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003011340A1 true WO2003011340A1 (fr) | 2003-02-13 |
Family
ID=7693160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008101 WO2003011340A1 (fr) | 2001-07-26 | 2002-07-19 | Formulation medicamenteuse destinee a une utilisation topique aux fins de therapie et de prophylaxie d'hyperhydrose |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE10136404A1 (fr) |
WO (1) | WO2003011340A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004084905A2 (fr) * | 2003-03-24 | 2004-10-07 | University Of Florida | Methodes de traitement de l'hyperhidrose idiopathique et de pathologies associees |
WO2006069998A2 (fr) | 2004-12-27 | 2006-07-06 | Beiersdorf Ag | Le compose glycopyrrolate dans des preparations cosmetiques |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
WO2014134510A1 (fr) * | 2013-02-28 | 2014-09-04 | Dermira, Inc. | Sels de glycopyrrolate |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
MD4369C1 (ro) * | 2011-03-04 | 2016-04-30 | Sosei R&D Ltd | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei |
KR20180091361A (ko) | 2017-02-06 | 2018-08-16 | 주식회사 퍼슨 | 발한억제 기능을 가지는 자외선 차단 화장료 조성물 및 이를 사용한 자외선 차단제의 제조방법 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004063726A1 (de) * | 2004-12-27 | 2006-07-06 | Beiersdorf Ag | Emulsionen enthaltend Glycopyrroniumbromid, Polyethylenglykol(2) stearylether und Polyethylenglykol(21) stearylether |
DE102005029386A1 (de) * | 2005-06-23 | 2007-01-11 | Beiersdorf Ag | Wirkstoffkombinationen aus Glycopyrroniumbromid und einem oder mehreren Hydrokolloiden |
DE102005029390A1 (de) * | 2005-06-23 | 2007-01-04 | Beiersdorf Ag | Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen |
DE102005029387B4 (de) | 2005-06-23 | 2018-12-27 | Beiersdorf Ag | Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyglyceryl(3)-Methylglucosedistearat |
DE102005029388B4 (de) * | 2005-06-23 | 2018-12-27 | Beiersdorf Ag | Wirkstoffkombinationen aus Glycopyrroniumbromid und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und/oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure |
DE102005029389A1 (de) * | 2005-06-23 | 2007-01-04 | Beiersdorf Ag | Wirkstoffkombinationen aus Glycopyrroniumbromid und dialkylsubstituierten Essigsäuren |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962505A (en) * | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
WO2000012087A1 (fr) * | 1998-08-31 | 2000-03-09 | Bobrove Arthur M | Traitement des bouffees de chaleur chez des sujets humains |
WO2001008681A1 (fr) * | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methodes d'administration de compositions de glycopyrrolates |
-
2001
- 2001-07-26 DE DE2001136404 patent/DE10136404A1/de not_active Ceased
-
2002
- 2002-07-19 WO PCT/EP2002/008101 patent/WO2003011340A1/fr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962505A (en) * | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
WO2000012087A1 (fr) * | 1998-08-31 | 2000-03-09 | Bobrove Arthur M | Traitement des bouffees de chaleur chez des sujets humains |
WO2001008681A1 (fr) * | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methodes d'administration de compositions de glycopyrrolates |
Non-Patent Citations (2)
Title |
---|
MAY J S ET AL: "Frey's syndrome: treatment with topical glycopyrrolate.", HEAD & NECK. UNITED STATES 1989 JAN-FEB, vol. 11, no. 1, January 1989 (1989-01-01), pages 85 - 89, XP008009263, ISSN: 1043-3074 * |
SEUKERAN D C ET AL: "The use of topical glycopyrrolate in the treatment of hyperhidrosis.", 1998, CLINICAL AND EXPERIMENTAL DERMATOLOGY, VOL. 23, NR. 5, PAGE(S) 204-205, ISSN: 0307-6938, XP001122802 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004084905A2 (fr) * | 2003-03-24 | 2004-10-07 | University Of Florida | Methodes de traitement de l'hyperhidrose idiopathique et de pathologies associees |
WO2004084905A3 (fr) * | 2003-03-24 | 2005-04-28 | Univ Florida | Methodes de traitement de l'hyperhidrose idiopathique et de pathologies associees |
WO2006069998A2 (fr) | 2004-12-27 | 2006-07-06 | Beiersdorf Ag | Le compose glycopyrrolate dans des preparations cosmetiques |
MD4369C1 (ro) * | 2011-03-04 | 2016-04-30 | Sosei R&D Ltd | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei |
US9259414B2 (en) | 2013-02-28 | 2016-02-16 | Dermira, Inc. | Glycopyrrolate salts |
US10004717B2 (en) | 2013-02-28 | 2018-06-26 | Dermira, Inc. | Glycopyrrolate salts |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US9006461B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
WO2014134510A1 (fr) * | 2013-02-28 | 2014-09-04 | Dermira, Inc. | Sels de glycopyrrolate |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US9610278B2 (en) | 2013-02-28 | 2017-04-04 | Dermira, Inc. | Glycopyrrolate salts |
US8859610B2 (en) | 2013-02-28 | 2014-10-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US11291652B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
EP3473615A1 (fr) * | 2013-02-28 | 2019-04-24 | Dermira, Inc. | Sels de glycopyrrolate |
US10543192B2 (en) | 2013-02-28 | 2020-01-28 | Dermira, Inc. | Glycopyrrolate salts |
US10548875B2 (en) | 2013-02-28 | 2020-02-04 | Dermira, Inc. | Glycopyrrolate salts |
US11291651B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
KR20180091361A (ko) | 2017-02-06 | 2018-08-16 | 주식회사 퍼슨 | 발한억제 기능을 가지는 자외선 차단 화장료 조성물 및 이를 사용한 자외선 차단제의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
DE10136404A1 (de) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69012591T2 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
EP0326034B1 (fr) | Preparation combinée pour le traitement des maladies et desordres des cellules et des fibres nerveuses | |
DE3875931T2 (de) | Verbesserung des eindringens in die haut durch verwendung von mischungen der freien base mit dem sauren additionssalz von wirkstoffen. | |
DE69829112T2 (de) | Butyrate Derivate zur Behandlung von Fibromyalgia und chronischem Müdigkeits-Syndrom | |
DE602004004399T2 (de) | Grün gefärbte topische pharmazeutische zusammensetzung auf der basis von metronidazol | |
DE60204322T2 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
DE3218761C2 (fr) | ||
DE68904922T2 (de) | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. | |
DE20122843U1 (de) | Fentanyl Zusammensetzung zur nasalen Anwendung | |
WO2003011340A1 (fr) | Formulation medicamenteuse destinee a une utilisation topique aux fins de therapie et de prophylaxie d'hyperhydrose | |
DE68917186T2 (de) | Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie. | |
DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
CH685099A5 (de) | Pharmazeutisches Präparat für die intranasale Anwendung. | |
EP0856312B1 (fr) | Utilisation du chlorure de trospium pour la fabrication d'un médicament pour le traitement de maladies de la vessie | |
DE69821498T2 (de) | Verwendung von amifostin | |
DE3116860C2 (fr) | ||
EP0996462A1 (fr) | Preparations pharmaceutiques combinees contenant de l'erythropoietine et de l'hemoglobine modifiee | |
EP0037488A2 (fr) | Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses | |
DE3330053A1 (de) | Retinoprotektor zur behandlung von inneren augenblutungen, myopischen, chorioretinalen dystrophien, erblichen netzhautdystrophien, -verbrennungen und zur vorbeugung vor verletzungen bei laserkoagulation | |
DE69331008T2 (de) | Verwendung von cotinin zur linderung des tabakentzugssyndrom | |
DE3324964C2 (fr) | ||
DE60022689T2 (de) | Pharmazeutische desinfektionsmittel, die usninsäure und ein ätherisches öl enthalten | |
DE60133284T2 (de) | Medizinisches kombinationspräparat zur behandlung von verletztem abnormem gewebe | |
DE69132145T2 (de) | Peritoneal wirksame medikamente | |
EP0820771A2 (fr) | Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un composé de magnésium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 69(1) EPO 1205A 090704 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |